{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:52:48Z","timestamp":1771980768871,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA174294"],"award-info":[{"award-number":["R01 CA174294"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s11307-020-01518-4","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T15:03:59Z","timestamp":1594652639000},"page":"1380-1391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer"],"prefix":"10.1007","volume":"22","author":[{"given":"Wen-Ting K","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirstin A","family":"Zettlitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Dahlbom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8487-823X","authenticated-orcid":false,"given":"Anna M","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"1518_CR1","volume-title":"EAU \u2013 ESTRO \u2013 ESUR \u2013 SIOG guidelines on prostate cancer","author":"N Mottet","year":"2018","unstructured":"Mottet N, Bellmunt J, Briers E, Bolla M, Bourke L, Cornford P, De Santis M, Henry AM, Joniau S, Lam TB, Mason MD, Van den Poel H, Van den Kwast TH, et al. (2018). EAU \u2013 ESTRO \u2013 ESUR \u2013 SIOG guidelines on prostate cancer"},{"key":"1518_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028\u20131038. https:\/\/doi.org\/10.1056\/NEJMoa1315815","journal-title":"N Engl J Med"},{"key":"1518_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/j.semnuclmed.2015.10.005","volume":"46","author":"S Evans-Axelsson","year":"2016","unstructured":"Evans-Axelsson S, Timmermand OV, Bjartell A, Strand SE, Elgqvist J (2016) Radioimmunotherapy for prostate Cancer-current status and future possibilities. Semin Nucl Med 46:165\u2013179. https:\/\/doi.org\/10.1053\/j.semnuclmed.2015.10.005","journal-title":"Semin Nucl Med"},{"key":"1518_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/cncr.24795","volume":"116","author":"ST Tagawa","year":"2010","unstructured":"Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH (2010) Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 116:1075\u20131083. https:\/\/doi.org\/10.1002\/cncr.24795","journal-title":"Cancer."},{"key":"1518_CR5","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","volume":"19","author":"ST Tagawa","year":"2013","unstructured":"Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM (2013) Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 19:5182\u20135191. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0231","journal-title":"Clin Cancer Res"},{"key":"1518_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13550-016-0181-z","volume":"6","author":"O Vilhelmsson Timmermand","year":"2016","unstructured":"Vilhelmsson Timmermand O, Larsson E, Ulmert D, Tran TA, Strand S (2016) Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2. EJNMMI Res 6:27. https:\/\/doi.org\/10.1186\/s13550-016-0181-z","journal-title":"EJNMMI Res"},{"key":"1518_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/pcan.2017.23","volume":"20","author":"RJS Calopedos","year":"2017","unstructured":"Calopedos RJS, Chalasani V, Asher R, Emmett L, Woo HH (2017) Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 20:352\u2013360. https:\/\/doi.org\/10.1038\/pcan.2017.23","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1518_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M et al (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85\u201390. https:\/\/doi.org\/10.2967\/jnumed.116.183194","journal-title":"J Nucl Med"},{"key":"1518_CR9","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/sj.onc.1203426","volume":"19","author":"Z Gu","year":"2000","unstructured":"Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE (2000) Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 19:1288\u20131296. https:\/\/doi.org\/10.1038\/sj.onc.1203426","journal-title":"Oncogene."},{"key":"1518_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/CJI.0b013e318031b53b","volume":"30","author":"T Olafsen","year":"2007","unstructured":"Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE (2007) Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 30:396\u2013405. https:\/\/doi.org\/10.1097\/CJI.0b013e318031b53b","journal-title":"J Immunother"},{"key":"1518_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2967\/jnumed.111.096453","volume":"53","author":"J Schwartz","year":"2012","unstructured":"Schwartz J, Humm JL, Divgi CR, Larson SM, O'Donoghue JA (2012) Bone marrow dosimetry using 124I-PET. J Nucl Med 53:615\u2013621. https:\/\/doi.org\/10.2967\/jnumed.111.096453","journal-title":"J Nucl Med"},{"key":"1518_CR12","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","volume":"23","author":"NH Bander","year":"2005","unstructured":"Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23:4591\u20134601. https:\/\/doi.org\/10.1200\/JCO.2005.05.160","journal-title":"J Clin Oncol"},{"key":"1518_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/1450-1147.89780","volume":"10","author":"KS Loke","year":"2011","unstructured":"Loke KS, Padhy AK, Ng DC, Goh AS, Divgi C (2011) Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review. World J Nucl Med 10:122\u2013138. https:\/\/doi.org\/10.4103\/1450-1147.89780","journal-title":"World J Nucl Med"},{"key":"1518_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.2005.03.8471","volume":"24","author":"DM Goldenberg","year":"2006","unstructured":"Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF (2006) Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 24:823\u2013834. https:\/\/doi.org\/10.1200\/JCO.2005.03.8471","journal-title":"J Clin Oncol"},{"key":"1518_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1089\/cbr.2014.1660","volume":"29","author":"CM van Rij","year":"2014","unstructured":"van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, Lutje S, McBride WJ, Oyen WJ, Boerman OC (2014) Pretargeted radioimmunotherapy of prostate cancer with an anti-TROP-2xanti-HSG bispecific antibody and a (177)Lu-labeled peptide. Cancer Biother Radiopharm 29:323\u2013329. https:\/\/doi.org\/10.1089\/cbr.2014.1660","journal-title":"Cancer Biother Radiopharm"},{"key":"1518_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1158\/0008-5472.CAN-06-0454","volume":"67","author":"V Kenanova","year":"2007","unstructured":"Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, Shively JE, Colcher D, Raubitschek AA, Wu AM (2007) Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res 67:718\u2013726. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0454","journal-title":"Cancer Res"},{"key":"1518_CR17","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/sj.bjc.6603806","volume":"96","author":"E El-Emir","year":"2007","unstructured":"El-Emir E, Dearling JL, Huhalov A, Robson MP, Boxer G, Neri D, van Dongen GA, Trachsel E, Begent RH, Pedley RB (2007) Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. Br J Cancer 96:1862\u20131870. https:\/\/doi.org\/10.1038\/sj.bjc.6603806","journal-title":"Br J Cancer"},{"key":"1518_CR18","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1021\/mp500164r","volume":"11","author":"NT Viola-Villegas","year":"2014","unstructured":"Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS (2014) Noninvasive imaging of PSMA in prostate tumors with (89)Zr-labeled huJ591 engineered antibody fragments: the faster alternatives. Mol Pharm 11:3965\u20133973. https:\/\/doi.org\/10.1021\/mp500164r","journal-title":"Mol Pharm"},{"key":"1518_CR19","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1158\/1078-0432.CCR-14-1452","volume":"20","author":"SM Knowles","year":"2014","unstructured":"Knowles SM, Tavare R, Zettlitz KA, Rochefort MM, Salazar FB, Jiang ZK, Reiter RE, Wu AM (2014) Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer. Clin Cancer Res 20:6367\u20136378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1452","journal-title":"Clin Cancer Res"},{"key":"1518_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2967\/jnumed.113.120873","volume":"55","author":"SM Knowles","year":"2014","unstructured":"Knowles SM, Zettlitz KA, Tavare R, Rochefort MM, Salazar FB, Stout DB, Yazaki PJ, Reiter RE, Wu AM (2014) Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody. J Nucl Med 55:452\u2013459. https:\/\/doi.org\/10.2967\/jnumed.113.120873","journal-title":"J Nucl Med"},{"key":"1518_CR21","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.7150\/thno.27679","volume":"8","author":"WK Tsai","year":"2018","unstructured":"Tsai WK, Zettlitz KA, Tavare R, Kobayashi N, Reiter RE, Wu AM (2018) Dual-modality immunoPET\/fluorescence imaging of prostate cancer with an anti-PSCA cys-minibody. Theranostics. 8:5903\u20135914. https:\/\/doi.org\/10.7150\/thno.27679","journal-title":"Theranostics."},{"key":"1518_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.semnuclmed.2008.05.002","volume":"38","author":"AI Kassis","year":"2008","unstructured":"Kassis AI (2008) Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med 38:358\u2013366. https:\/\/doi.org\/10.1053\/j.semnuclmed.2008.05.002","journal-title":"Semin Nucl Med"},{"key":"1518_CR23","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3389\/fphar.2018.00996","volume":"9","author":"BM Bavelaar","year":"2018","unstructured":"Bavelaar BM, Lee BQ, Gill MR, Falzone N, Vallis KA (2018) Subcellular targeting of theranostic radionuclides. Front Pharmacol 9:996. https:\/\/doi.org\/10.3389\/fphar.2018.00996","journal-title":"Front Pharmacol"},{"key":"1518_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/jlcr.3622","volume":"16","author":"WK Tsai","year":"2018","unstructured":"Tsai WK, Wu AM (2018) Aligning physics and physiology: engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm 16:693\u2013714. https:\/\/doi.org\/10.1002\/jlcr.3622","journal-title":"J Labelled Comp Radiopharm"},{"key":"1518_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.nucmedbio.2008.11.001","volume":"36","author":"M Hens","year":"2009","unstructured":"Hens M, Vaidyanathan G, Welsh P, Zalutsky MR (2009) Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. Nucl Med Biol 36:117\u2013128. https:\/\/doi.org\/10.1016\/j.nucmedbio.2008.11.001","journal-title":"Nucl Med Biol"},{"key":"1518_CR26","doi-asserted-by":"crossref","unstructured":"Rogers BE, Franano FN, Duncan JR, Edwards WB, Anderson CJ, Connett JM, Welch MJ. Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res. 1995; 55: 5714s\u201320s. doi:","DOI":"10.1097\/00002371-199408000-00078"},{"key":"1518_CR27","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1073\/pnas.051624698","volume":"98","author":"DC Saffran","year":"2001","unstructured":"Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A (2001) Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 98:2658\u20132663. https:\/\/doi.org\/10.1073\/pnas.051624698","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1518_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/1078-0432.CCR-18-1382","volume":"25","author":"M Zhang","year":"2018","unstructured":"Zhang M, Kobayashi N, Zettlitz KA, Kono EA, Yamashiro JM, Tsai WK, Jiang ZK, Tran CP, Wang C, Guan J, Wu AM, Reiter RE (2018) Near-infrared-dye labeled anti-prostate stem cell antigen minibody enables real-time fluorescence imaging and targeted surgery in translational mouse models. Clin Cancer Res 25:188\u2013200. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1382","journal-title":"Clin Cancer Res"},{"key":"1518_CR29","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1158\/1078-0432.CCR-17-0855","volume":"23","author":"KA Zettlitz","year":"2017","unstructured":"Zettlitz KA, Tavare R, Knowles SM, Steward KK, Timmerman JM, Wu AM (2017) ImmunoPET of malignant and normal B cells with (89)Zr- and (124)I-labeled obinutuzumab antibody fragments reveals differential CD20 internalization in vivo. Clin Cancer Res 23:7242\u20137252. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0855","journal-title":"Clin Cancer Res"},{"key":"1518_CR30","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/nprot.2006.175","volume":"1","author":"JK Sosabowski","year":"2006","unstructured":"Sosabowski JK, Mather SJ (2006) Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nat Protoc 1:972\u2013976. https:\/\/doi.org\/10.1038\/nprot.2006.175","journal-title":"Nat Protoc"},{"key":"1518_CR31","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00259-010-1433-1","volume":"37","author":"EJ Lepin","year":"2010","unstructured":"Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM (2010) An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging 37:1529\u20131538. https:\/\/doi.org\/10.1007\/s00259-010-1433-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1518_CR32","doi-asserted-by":"crossref","unstructured":"Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003; 2: 131\u20137. doi:","DOI":"10.1162\/153535003322556877"},{"key":"1518_CR33","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3109\/0284186X.2011.582517","volume":"50","author":"E Larsson","year":"2011","unstructured":"Larsson E, Ljungberg M, Strand SE, Jonsson BA (2011) Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for pre-clinical dosimetry studies. Acta Oncol 50:973\u2013980. https:\/\/doi.org\/10.3109\/0284186X.2011.582517","journal-title":"Acta Oncol"},{"key":"1518_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrc3925","volume":"15","author":"SM Larson","year":"2015","unstructured":"Larson SM, Carrasquillo JA, Cheung NK, Press OW (2015) Radioimmunotherapy of human tumours. Nat Rev Cancer 15:347\u2013360. https:\/\/doi.org\/10.1038\/nrc3925","journal-title":"Nat Rev Cancer"},{"key":"1518_CR35","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46: 1023\u20137. doi:"},{"issue":"Suppl 6","key":"1518_CR36","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1289\/ehp.97105s61403","volume":"105","author":"MG Stabin","year":"1997","unstructured":"Stabin MG (1997) Health concerns related to radiation exposure of the female nuclear medicine patient. Environ Health Perspect 105(Suppl 6):1403\u20131409. https:\/\/doi.org\/10.1289\/ehp.97105s61403","journal-title":"Environ Health Perspect"},{"key":"1518_CR37","doi-asserted-by":"crossref","unstructured":"Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006; 47: 1127\u201335. doi:","DOI":"10.1001\/archotol.132.8.886-a"},{"key":"1518_CR38","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1073\/pnas.1316922111","volume":"111","author":"R Tavare","year":"2014","unstructured":"Tavare R, McCracken MN, Zettlitz KA, Knowles SM, Salazar FB, Olafsen T, Witte ON, Wu AM (2014) Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc Natl Acad Sci U S A 111:1108\u20131113. https:\/\/doi.org\/10.1073\/pnas.1316922111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1518_CR39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"JA Violet","year":"2019","unstructured":"Violet JA, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Thang SP, Eu P, Scalzo M, Murphy D, Williams SG et al (2019) Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole body tumor dosimetry with treatment outcomes. J Nucl Med 60:517\u2013523. https:\/\/doi.org\/10.2967\/jnumed.118.219352","journal-title":"J Nucl Med"},{"key":"1518_CR40","unstructured":"Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med. 2005; 46: 1812\u20138. doi:"},{"key":"1518_CR41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12149-013-0685-9","volume":"27","author":"M Sakata","year":"2013","unstructured":"Sakata M, Oda K, Toyohara J, Ishii K, Nariai T, Ishiwata K (2013) Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Ann Nucl Med 27:285\u2013296. https:\/\/doi.org\/10.1007\/s12149-013-0685-9","journal-title":"Ann Nucl Med"},{"key":"1518_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11307-019-01386-7","volume":"22","author":"KA Zettlitz","year":"2019","unstructured":"Zettlitz KA, Tsai WK, Knowles SM, Salazar FB, Kobayashi N, Reiter RE, Wu AM (2019) [(89)Zr]A2cDb immuno-PET of prostate cancer in a human prostate stem cell antigen knock-in (hPSCA KI) syngeneic model. Mol Imaging Biol 22:367\u2013376. https:\/\/doi.org\/10.1007\/s11307-019-01386-7","journal-title":"Mol Imaging Biol"},{"key":"1518_CR43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","volume":"15","author":"WL Hwang","year":"2018","unstructured":"Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS (2018) Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol 15:477\u2013494. https:\/\/doi.org\/10.1038\/s41571-018-0046-7","journal-title":"Nat Rev Clin Oncol"},{"key":"1518_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13550-020-0600-z","volume":"10","author":"T B\u00e4ck","year":"2020","unstructured":"B\u00e4ck T, Jennbacken K, Olafsen T, Hagberg-Thulin M, Lindegren S, Jensen H, Yazaki PJ, Palm S, Albertsson P, Damber JE, Wu AM, Welen K (2020) Targeted alpha therapy with astatine-211 labeled anti-PSCA A11 minibody shows strong antitumor efficacy in prostate cancer xenografts and bone microtumors. Eur J NuclMedMolecImag Res 10:10. https:\/\/doi.org\/10.1186\/s13550-020-0600-z","journal-title":"Eur J NuclMedMolecImag Res"},{"key":"1518_CR45","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.117.190124","volume":"58","author":"UA Haberkorn","year":"2017","unstructured":"Haberkorn UA, Giesel F, Morgenstern A, Kratochwil C (2017) The future of radioligand therapy: alpha, beta or both? J Nucl Med 58:1017\u20131018. https:\/\/doi.org\/10.2967\/jnumed.117.190124","journal-title":"J Nucl Med"},{"key":"1518_CR46","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A (2016) 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate Cancer. J Nucl Med 57:1941\u20131944. https:\/\/doi.org\/10.2967\/jnumed.116.178673","journal-title":"J Nucl Med"},{"key":"1518_CR47","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, Haberkorn U, Giesel FL, Morgenstern A (2017) Targeted alpha-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med 58:1624\u20131631. https:\/\/doi.org\/10.2967\/jnumed.117.191395","journal-title":"J Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-020-01518-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-020-01518-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-020-01518-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T15:44:45Z","timestamp":1667403885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-020-01518-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1518"],"URL":"https:\/\/doi.org\/10.1007\/s11307-020-01518-4","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"13 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"AM Wu holds ownership interest in and is a consultant\/advisory board member for ImaginAb, Inc. The other authors do not have potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All applicable institutional and\/or national guidelines for the care and use of animals were followed","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of Animal Rights"}}]}}